Market Cap 3.28M
Revenue (ttm) 170,000.00
Net Income (ttm) -17.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,188.24%
Debt to Equity Ratio 0.00
Volume 73,600
Avg Vol 114,156
Day's Range N/A - N/A
Shares Out 2.85M
Stochastic %K 11%
Beta 1.21
Analysts Strong Sell
Price Target $14.00

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 352 448 7797
Fax: 352 480 4620
Address:
2117 SW Highway 484, Ocala, United States
ultimatebastos
ultimatebastos Jan. 30 at 1:01 PM
$AIM I like the fact that the bigpussycatofwallstreet is still here. Makes me think.🤔
0 · Reply
S_Templar
S_Templar Jan. 29 at 8:12 PM
$AIM the rights offering will delute right??? Which will probably drive the stock below $1, right?? Then what??? I don't think a R/S is possible. Delisting????(Ok with me) I'm asking not critiquing.
1 · Reply
earlyRetirement14
earlyRetirement14 Jan. 29 at 2:22 PM
$AIM still pumping this POS huh? What are they looking at their 12th Reverse Split?
2 · Reply
peepthestamp
peepthestamp Jan. 29 at 1:28 PM
0 · Reply
TheLionofwallstreet
TheLionofwallstreet Jan. 29 at 12:19 AM
0 · Reply
jonjonson1234
jonjonson1234 Jan. 28 at 9:27 PM
$AIM From the most recent 10-Q "Total stockholders’ equity September 30, 2025 -$6,077,000 December 31, 2024 -$1,322,000" "On December 11, 2024, the Company received an official notice of noncompliance with the Exchange’s continued listing requirements. This includes the need for the Company to have stockholders’ equity of $6,000,000 or more. The Exchange’s review showed that the Company was not in compliance with that requirement. As required, the Company submitted a plan (the “Plan”) to the Exchange illustrating how it can regain compliance by June 11, 2026. The Exchange accepted the Plan on February 26, 2025. If the Company is not able to regain compliance by June 11, 2026, its common stock may be delisted from the Exchange." Given the downward trend in stockholders' equity, I cannot say that I feel great optimism that they will that number from -$6 million to +$6 million by June.
1 · Reply
sschmid1
sschmid1 Jan. 28 at 6:55 AM
$AIM Maybe it's a coincidence, but the shift in the $AIM timeline looks highly tactical. The AACR Immuno-Oncology Conference (Feb 18-21) has a very specific rule: abstract titles and authors are published on the website on Feb 9th at 1 p.m. ET. Management just moved the 'Ownership Day' to Feb 9th and the 'Record Date' to Feb 10th. This means the market gets the AACR 'signal' (via the title) exactly 4 hours before the window closes for rights eligibility. If that title is 'Late-Breaking' and positive, the Feb 10th audit is going to be a very crowded room for the shorts. The 'Audit' and the 'Science' are now officially colliding. https://www.aacr.org/meeting/aacr-io-2026/ https://www.aacr.org/about-the-aacr/newsroom/media-advisories/register-today-aacr-immuno-oncology-conference-february-18-21-2026/
2 · Reply
uuddlrlr
uuddlrlr Jan. 27 at 9:59 PM
$AIM "Certain of AIM’s leadership have indicated to the Company on a non-binding basis that they intend to participate in the Rights Offering, including Board member and Chief Executive Officer Thomas K. Equels." Shareholders must be thrilled to know that CEO Equels is going to participate in this latest attempt to raise money. CEO Equels and other insiders will be very thankful to know that they will continue to collect a salaries for delivering all time stock price lows to investors.
1 · Reply
igor9040
igor9040 Jan. 27 at 9:43 PM
0 · Reply
TalonKarrde
TalonKarrde Jan. 27 at 6:29 PM
$NWBO A Dendritic Cell–Centered Immune Circuit for Cold Solid Tumors $AZN $AIM $MRK Rebuilding Immunotherapy as a Manufacturing Pipeline for Pancreatic Ductal Adenocarcinoma https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177226439
1 · Reply
Latest News on AIM
Aimia Inc. (AIM:CA) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:51 PM EST - 2 months ago

Aimia Inc. (AIM:CA) Q3 2025 Earnings Call Transcript


AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Oct 20, 2025, 9:15 AM EDT - 3 months ago

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit


AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Aug 21, 2025, 9:00 AM EDT - 5 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment


Why Is Micro-Cap AIM ImmunoTech Stock Surging?

Jul 28, 2025, 11:12 AM EDT - 6 months ago

Why Is Micro-Cap AIM ImmunoTech Stock Surging?


AIM ImmunoTech Resumes Trading on NYSE American

Jun 17, 2025, 8:55 AM EDT - 8 months ago

AIM ImmunoTech Resumes Trading on NYSE American


AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Jun 11, 2025, 4:15 PM EDT - 8 months ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split


Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript

May 13, 2025, 9:54 AM EDT - 9 months ago

Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript


AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 9:19 AM EDT - 10 months ago

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript


Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript

Mar 28, 2025, 11:39 AM EDT - 11 months ago

Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript


ultimatebastos
ultimatebastos Jan. 30 at 1:01 PM
$AIM I like the fact that the bigpussycatofwallstreet is still here. Makes me think.🤔
0 · Reply
S_Templar
S_Templar Jan. 29 at 8:12 PM
$AIM the rights offering will delute right??? Which will probably drive the stock below $1, right?? Then what??? I don't think a R/S is possible. Delisting????(Ok with me) I'm asking not critiquing.
1 · Reply
earlyRetirement14
earlyRetirement14 Jan. 29 at 2:22 PM
$AIM still pumping this POS huh? What are they looking at their 12th Reverse Split?
2 · Reply
peepthestamp
peepthestamp Jan. 29 at 1:28 PM
0 · Reply
TheLionofwallstreet
TheLionofwallstreet Jan. 29 at 12:19 AM
0 · Reply
jonjonson1234
jonjonson1234 Jan. 28 at 9:27 PM
$AIM From the most recent 10-Q "Total stockholders’ equity September 30, 2025 -$6,077,000 December 31, 2024 -$1,322,000" "On December 11, 2024, the Company received an official notice of noncompliance with the Exchange’s continued listing requirements. This includes the need for the Company to have stockholders’ equity of $6,000,000 or more. The Exchange’s review showed that the Company was not in compliance with that requirement. As required, the Company submitted a plan (the “Plan”) to the Exchange illustrating how it can regain compliance by June 11, 2026. The Exchange accepted the Plan on February 26, 2025. If the Company is not able to regain compliance by June 11, 2026, its common stock may be delisted from the Exchange." Given the downward trend in stockholders' equity, I cannot say that I feel great optimism that they will that number from -$6 million to +$6 million by June.
1 · Reply
sschmid1
sschmid1 Jan. 28 at 6:55 AM
$AIM Maybe it's a coincidence, but the shift in the $AIM timeline looks highly tactical. The AACR Immuno-Oncology Conference (Feb 18-21) has a very specific rule: abstract titles and authors are published on the website on Feb 9th at 1 p.m. ET. Management just moved the 'Ownership Day' to Feb 9th and the 'Record Date' to Feb 10th. This means the market gets the AACR 'signal' (via the title) exactly 4 hours before the window closes for rights eligibility. If that title is 'Late-Breaking' and positive, the Feb 10th audit is going to be a very crowded room for the shorts. The 'Audit' and the 'Science' are now officially colliding. https://www.aacr.org/meeting/aacr-io-2026/ https://www.aacr.org/about-the-aacr/newsroom/media-advisories/register-today-aacr-immuno-oncology-conference-february-18-21-2026/
2 · Reply
uuddlrlr
uuddlrlr Jan. 27 at 9:59 PM
$AIM "Certain of AIM’s leadership have indicated to the Company on a non-binding basis that they intend to participate in the Rights Offering, including Board member and Chief Executive Officer Thomas K. Equels." Shareholders must be thrilled to know that CEO Equels is going to participate in this latest attempt to raise money. CEO Equels and other insiders will be very thankful to know that they will continue to collect a salaries for delivering all time stock price lows to investors.
1 · Reply
igor9040
igor9040 Jan. 27 at 9:43 PM
0 · Reply
TalonKarrde
TalonKarrde Jan. 27 at 6:29 PM
$NWBO A Dendritic Cell–Centered Immune Circuit for Cold Solid Tumors $AZN $AIM $MRK Rebuilding Immunotherapy as a Manufacturing Pipeline for Pancreatic Ductal Adenocarcinoma https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177226439
1 · Reply
jonjonson1234
jonjonson1234 Jan. 27 at 3:48 PM
$AIM " Purchasers of Units in the Rights Offering will experience an immediate dilution of the net tangible book value per share of our common stock. Our net tangible book value as of September 30, 2025 was approximately negative $8,117,686, or negative $2.94 per share of our common stock (based upon 2,764,188 shares of our common stock outstanding on September 30, 2025). Net tangible book value per share is equal to our total tangible assets less our total liabilities, divided by the number of shares of our outstanding common stock." Myself, I would never buy shares in a company with a negative book value. But, hey: "to each his own"
2 · Reply
ultimatebastos
ultimatebastos Jan. 26 at 3:14 PM
$AIM I feel like a traitor but it looks as if the only way of getting a little bit of my money back is joining the croocks into the offering.
1 · Reply
ultimatebastos
ultimatebastos Jan. 26 at 2:32 PM
$AIM I’m in doubt deep under water. The last prefered stock offering was to reward long term retailors. They took our money and ran. What’s different now is that 90% o the real stock is in hands of the croocks. I might take on the offering but it’s just disgusting how they robbed us.
2 · Reply
melodicalmind
melodicalmind Jan. 25 at 6:09 PM
0 · Reply
sschmid1
sschmid1 Jan. 25 at 10:03 AM
$AIM Here is my personal plan: I’m looking to round my position up to a multiple of ~1,222 shares ahead of next week, because I want to be structurally positioned to fully participate (incl. potential over-subscription) in case blockbuster Duripanc data is released. Not predicting anything — just preparing for a high-impact outcome rather than reacting after the fact. Everyone should do their own math and risk assessment.
1 · Reply
sschmid1
sschmid1 Jan. 25 at 8:54 AM
$AIM Let me add some substance to my post from yesterday 1) Why not before the record date (Feb 4) If AIM released blockbuster DURIPANC data before the Class G record date: Traders could buy shares just to get rights, then flip Shorts could: • cover temporarily • re-short into rights-related selling • The market would price: • data and • financing uncertainty at the same time That recreates Mistake #2 (2025): Great data immediately capped by structural noise.
2 · Reply
sschmid1
sschmid1 Jan. 25 at 5:22 AM
$AIM Analyzing the $AIM S-1/A (Jan 23) math for those looking to participate in the upcoming Rights Offering (Record Date: Feb 4). To qualify for the $1.34 conversion via the Series G Units, there are a few technical hurdles to note: • Participation Threshold: You need ~1,222 shares (or Participating Securities) to subscribe for 1 full Unit ($1,000). • Rounding Rule: Fractional rights are rounded down to the nearest whole number. If you own 1,200 shares, your basic entitlement is 0 units. • Over-Subscription: To apply for 'leftover' units, you must first exercise your Basic Subscription Right in full. This means holders with fewer than 1,222 shares are mathematically ineligible for both basic and over-subscription. If you are following the #DURIPANC clinical path and want to participate in the $1.34 pricing, check your share count before the Feb 4th deadline. Post-split positions under 1,222 shares likely won't see rights in their accounts.
1 · Reply
dmat12
dmat12 Jan. 24 at 2:29 PM
$AIM Now would be a great time for Equels and Kellner to take large positions in this new offering and show some confidence in AIM.
2 · Reply
sschmid1
sschmid1 Jan. 24 at 8:04 AM
$AIM If $AIM management actually learned from the 2019 and July 2025 failures, they won't drop the Phase 2 DURIPANC results before the record date. The 'Blockbuster' move would be Feb 5th. No earlier. There is a specific structural reason why that date changes the game for shorts.
2 · Reply
melodicalmind
melodicalmind Jan. 23 at 11:39 PM
$AIM trying to raise 12M$ from existing , and truthfully, upset shareholders (not to mention the attempt to attract new ones) is a ballsy move, especially at the price they’re offering. As a company, either… 1. You’re confident about the results of your trials AND / OR 2. Somehow the synthetic shares theory is still intact and they need flush it out this way AND / OR 3. You’d rather avoid new debt , considering you already plan to eliminate at least half of this raised money to pay your existing debt. It’s mostly scenario 3, but I would like to believe it’s probably 1 too. If 1 doesn’t happen, you’re just being hopeful that people will still believe in you after the way the company has performed, which would be stupid, and I don’t think they are stupid. I’d keep the internal fraud possibilities out of equation for now.
1 · Reply
ultimatebastos
ultimatebastos Jan. 23 at 8:01 PM
$AIM same deal as the preferential shares. They just deleted those after.
0 · Reply
HjalmarTheGreat
HjalmarTheGreat Jan. 23 at 7:04 PM
$AIM Doing the math here, and this is highly dilutive. Was nice knowing you all for the past hour.
0 · Reply